Centre for Neuroscience of Speech, University of Melbourne, Australia; Department of Neurology, Royal Melbourne Hospital, Melbourne Australia.
The Bionics Institute, East Melbourne, Australia; Department of Medical Bionics, The University of Melbourne, Australia.
Autoimmun Rev. 2018 Dec;17(12):1202-1209. doi: 10.1016/j.autrev.2018.06.010. Epub 2018 Oct 11.
Multiple sclerosis produces neurological impairments that are variable in duration, severity and quality. Speech is frequently impaired, resulting in decreased communication skills and quality of life. Advancements in technology now makes it possible to use quantitative acoustic assessment of speech as biomarkers of disease progression.
Four domains of speech have been identified: articulation (slow articulation and imprecise consonants), voice (pitch and loudness instability), respiration (decreased phonatory time and expiratory pressure) and prosody (longer and frequent pauses, deficient loudness control). Studies also explored I) predictive models for diagnosis of MS and of ataxia using speech variables, II) the relationship of dysarthria with cognition and III) very few studies correlated neuroimaging with dysarthria. We could not identify longitudinal studies of speech or dysarthria in Multiple Sclerosis.
Refinement of objective measures of speech has enhanced our understanding of Multiple Sclerosis-related deficits in cross-sectional analysis while both integrative and longitudinal studies are identified as major gaps. This review highlights the potential for using quantitative acoustic assessments as clinical endpoints for diagnosing, monitoring progression and treatment in disease modifying trials.
多发性硬化症会导致神经系统损伤,其持续时间、严重程度和质量各不相同。言语常常受到影响,导致沟通能力下降和生活质量降低。技术的进步现在使得使用语音的定量声学评估作为疾病进展的生物标志物成为可能。
已经确定了四个语音领域:发音(发音缓慢和辅音不准确)、语音(音高和响度不稳定)、呼吸(发音时间和呼气压力减少)和韵律(停顿时间更长、更频繁,音量控制不足)。研究还探讨了 I)使用语音变量预测多发性硬化症和共济失调诊断的模型,II)构音障碍与认知的关系,以及 III)极少数研究将神经影像学与构音障碍相关联。我们无法确定多发性硬化症中语音或构音障碍的纵向研究。
对语音的客观测量方法的改进增强了我们对横断面分析中与多发性硬化症相关的缺陷的理解,同时也确定了综合和纵向研究是主要的空白。本综述强调了使用定量声学评估作为临床终点的潜力,用于诊断、监测疾病修正试验中的进展和治疗。